Abstract
Overview
Introduction
The dynamic MS market continues to grow unabated; seven major market revenues
increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the
highly successful beta-interferon brands, Teva' s Copaxone (glatiramer
acetate), and the recent relaunch of Tysabri; the first launch of a new MS
treatment for six years.
Scope
- This report focuses on the leading disease-modifying therapies used to
treat MS, with seven major market (7MM) sales and volume forecasts to 2016
- Assessment of current and future opportunities and threats in the MS
market across the 7MMs
- Future market events that are expected to affect drug revenues are
discussed and quantified for each of the 7MMs
- Lifecycle management case studies show how previously successful
strategies should be applied in the current and future MS market
Report Highlights
Despite the comparatively large MS population, the UK only accounted for 1.1%
of the 7MM total in 2006. Datamonitor believes the UK has potential to be a
much more profitable and attractive MS market. If treatment rates were on par
with Germany, the UK market could have been worth $293m in 2006-almost six
times higher than the actual value.
In order to successfully position a new drug class in the market, future
market players must have a clear and focused marketing strategy. With
Copaxone-launched in 1997-Teva has set the benchmark, and by utilizing similar
tactics, future MS players can successfully position novel therapies in the
market.
There remains a large opportunity for current and future players to cement and
develop their positions in the MS market. To ensure continued revenue and to
minimize franchise risk companies can follow Biogen Idec' s strategy to market
two or more products and show commitment to the MS community through long-term
franchise investment.
Reasons to Purchase
- Assess the impact of events such as patent expiries and new product
launches on the sales of key marketed brands
- Quantify the future size of the MS market, in terms of volume and value,
in each of the 7MM
- Identify key lifecycle management strategies that can ensure growth in the
competitive MS market
| 
View Cart
